Wave Life Sciences Ltd. (NASDAQ:WVE – Get Rating) Director Ra Capital Management, L.P. purchased 9,480,052 shares of the company’s stock in a transaction that occurred on Thursday, June 16th. The stock was bought at an average price of $2.15 per share, with a total value of $20,382,111.80. Following the purchase, the director now owns 17,202,009 shares of the company’s stock, valued at approximately $36,984,319.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Wave Life Sciences stock opened at $2.40 on Friday. The company has a market cap of $147.00 million, a PE ratio of -1.13 and a beta of 0.51. The company has a fifty day moving average price of $1.75 and a two-hundred day moving average price of $2.33. Wave Life Sciences Ltd. has a 12 month low of $1.16 and a 12 month high of $7.30.
Wave Life Sciences (NASDAQ:WVE – Get Rating) last released its quarterly earnings data on Thursday, May 12th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.06). The business had revenue of $1.75 million during the quarter, compared to analyst estimates of $3.75 million. Wave Life Sciences had a negative return on equity of 558.73% and a negative net margin of 275.31%. On average, research analysts predict that Wave Life Sciences Ltd. will post -2.02 EPS for the current year.
WVE has been the subject of a number of research analyst reports. StockNews.com initiated coverage on shares of Wave Life Sciences in a research note on Thursday, March 31st. They issued a “hold” rating for the company. HC Wainwright dropped their price target on shares of Wave Life Sciences from $10.00 to $8.00 in a research note on Friday, May 13th.
About Wave Life Sciences (Get Rating)
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression.
- Get a free copy of the StockNews.com research report on Wave Life Sciences (WVE)
- Ciena Stock Giving Window of Opportunity
- Zai Lab Stock Has Fallen to Value Levels
- Are These Cheap Copper Stocks Right For Your Portfolio?
- It’s A Comfortable Time To Buy Steelcase
- Worthington Posts Strong Results, But Earnings Fall On One-Off Adjustments
Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.